Jaime del Barrio Seoane

Treatment of atopic dermatitis with abrocitinib in real practice in Spain doi: 10.1111/ijd.1734 Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe for treating moderate-to-severe atopic dermatitis (AD) - Retrospective multicenter study involving 76 adult patients with moderate-to-severe AD who started abrocitinib treatment in 15 Spanish hospitals - Abrocitinib 100 or 200 mg daily (36.84% were naive to advanced therapies) - Baseline mean EASI score was 21.79 - At Week 24 EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75 - 18.42% discontinued treatment mainly due to inefficacy or adverse effects - 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma https://lnkd.in/edyNvdhq

https://lnkd.in/g2hC695G Article Title: Long-term survival after Acute Ischemic Stroke by types of reperfusion therapy, sex and chronic treatments of cardiovascular conditions Author(s): José Luis Clua-Espuny*, Sònia Abilleira, Queralt-Tomas M Lluïsa, González-Henares MA, Muria-Subirats E, Ballesta-Ors J and Gil-Guillen V Fco Journal: International Journal of Pharmaceutical Sciences and Developmental Research Journal ISSN: 2640-7760 Abstract: Purpose: Compare long-term survival by sex after reperfusion therapies with simultaneous medical therapy of cardiovascular conditions. Methods: AIS patients identified from the population-based register between 01Jan2011 and 31Dec2012 and classified into: 1) AIS + intravenous thrombolysis [group I], 2) AIS + mechanical thrombectomy with or without intravenous thrombolysis [group II], and 3) AIS + medical therapy alone (no reperfusion therapies) [group III]. Follow-up went through up until December 2016. Statistical approaches were employed for analyzing survival outcomes and their relationship with reperfusion therapy. #Acuteischemicstroke #Revascularizationtherapy #Sex #Chroniccomorbidities #Longtermsurvival #Pharmacy #Pharmacology #PharmaceuticalSciences #ClinicalPharmacy #MedicinalChemistry #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #Pharmacogenomics #Toxicology #Pharmaceutics #Biopharmaceutics #Pharmacognosy #PharmaceuticalChemistry #PharmacyPractice #CommunityPharmacy #HospitalPharmacy #IndustrialPharmacy #RegulatoryAffairs #DrugFormulation #DrugDelivery #PharmacyManagement #PharmaceuticalTechnology #PharmacyEducation #ClinicalTrials

**2024 EHA | New Generation BCL-2 Inhibitor Sonrotoclax Expected to Be a New Treatment Option for RRMM** The 29th Annual Meeting of the European Hematology Association (EHA) in Madrid, Spain, presented a study on Sonrotoclax (BGB-11417), a new-generation BCL-2 inhibitor, combined with dexamethasone for relapsed/refractory multiple myeloma (RRMM) patients with t(11;14). **Study Background** BCL-2 protein helps multiple myeloma (MM) cells evade apoptosis. MM cells with t(11;14) have high BCL-2 expression. Sonrotoclax has ten times the BCL-2 inhibitory ability of first-generation inhibitors and a shorter half-life. The ongoing BGB-11417-105 trial evaluates Sonrotoclax with dexamethasone ± carfilzomib/daratumumab/pomalidomide in RRMM patients with t(11;14). **Study Design** Patients were RRMM with t(11;14), having failed at least three treatments. They received escalating doses of Sonrotoclax (80-640 mg) with dexamethasone weekly. Primary endpoints were safety/tolerability, maximum tolerated dose (MTD), and recommended dose for the expansion phase (RDFE). **Study Results** As of March 25, 2024, 32 patients received 640 mg Sonrotoclax with dexamethasone. The median follow-up was 4.6 months. The ORR was 75%, with a ≥VGPR rate of 50%. The complete response (≥CR) rate was 21%, and the median duration of response (DOR) was 8 months. **Safety** No dose-limiting toxicities were observed. Common treatment-emergent adverse events included fatigue, insomnia, and gastrointestinal issues. Four patients experienced hematologic TEAEs, and two deaths were unrelated to treatment. **Conclusion** Sonrotoclax (640 mg) with dexamethasone was well tolerated in heavily pretreated RRMM patients with t(11;14), providing deep and durable responses. The study continues to explore Sonrotoclax with other novel agents. **Professor Lu Jin** Lu Jin, from Peking University People's Hospital, highlighted the potential of Sonrotoclax for MM patients with t(11;14), noting the need for further exploration of BCL-2 inhibitors in plasma cell diseases. 🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine In China for preliminary evaluation!  WhatsApp: +8613717959070 Email: [email protected] #2024EHA #Sonrotoclax #RRMM #BCL2Inhibitor #MultipleMyeloma #Hematology #NewTreatment #CancerResearch

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis Monthly lebrikizumab maintenance dosing sustained clear or almost-clear skinfor up to three years in the vast majority (more than 80%) of ADvocate 1 and 2 responders Nearly 87 percent of patients taking lebrikizumab did not require either high-potency topical corticosteroids or systemic treatments during the three-year period The safety profile at three years was consistent with the previously published two-year results BARCELONA, Spain I September 25, 2024 I More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing. Almirall S.A. (BME: ALM) announced these new long-term results from the ADjoin long-term extension study, which will be presented as a late breaker at the European Academy of Dermatology and Venereology (EADV) Congress from Sept. 25-28 in Amsterdam, Netherlands.1 Lebrikizumab is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity.2,3,4, The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.5,6 “Moderate-to-severe atopic dermatitis imposes a significant burden on patients, affecting their quality of life and overall wellbeing,” said Prof. Dr. med. Diamant Thaçi, Director at the Institute and Comprehensive Centre for Inflammation Medicine, in Lübeck, Germany. “These new three-year clinical data demonstrate the potential this biologic treatment has to provide sustained relief from this disease, offering long-term benefits to people living with this chronic and relapsing condition.” Patients taking lebrikizumab who completed 52 weeks in ADvocate 1 or 2 could enroll in ADjoin for an additional 100 weeks of continued treatment (up to 152 weeks of continuous treatment). Patients in this analysis of the long-term extension trial received treatment either 250 mg every two weeks (Q2W) or once monthly (Q4W). The approved maintenance dose of lebrikizumab is 250 mg Q4W. These data presented are part of ADjoin, the long-term extension study of the lebrikizumab trials, and include participants who responded to lebrikizumab treatment at Week 16 from ADvocate 1 and ADvocate 2.1 Source- https://lnkd.in/gzJwFbae #news #pipeline #business #trend #trend